Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Prognostic Usefulness of Maximum Standardized Uptake Value on FDG-PET in Surgically Resected Non-small-cell Lung Cancer

수술로 제거된 비소세포폐암의 예후 예측에 있어 FDG-PET 최대 표준화 섭취계수의 유용성

  • Nguyen Xuan Canh (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Lee Won-Woo (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Sung Sook-Whan (Department of Thoracic Surgery, Seoul National University College of Medicine) ;
  • Jheon Sang-Hoon (Department of Thoracic Surgery, Seoul National University College of Medicine) ;
  • Kim Yu-Kyeong (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Lee Dong-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Chung June-Key (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Lee Myung-Chul (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Kim Sang-Eun (Department of Nuclear Medicine, Seoul National University College of Medicine)
  • ;
  • 이원우 (서울대학교 의과대학 핵의학교실) ;
  • 성숙환 (서울대학교 의과대학 흉부외과학교실) ;
  • 전상훈 (서울대학교 의과대학 흉부외과학교실) ;
  • 김유경 (서울대학교 의과대학 핵의학교실) ;
  • 이동수 (서울대학교 의과대학 핵의학교실) ;
  • 정준기 (서울대학교 의과대학 핵의학교실) ;
  • 이명철 (서울대학교 의과대학 핵의학교실) ;
  • 김상은 (서울대학교 의과대학 핵의학교실)
  • Published : 2006.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: FDG uptake on positron omission tomography (PET) has been considered a prognostic indicator in non-small cell lung cancer (NSCLC). The aim of this study was to assess the clinical significance of maximum value of SUV (maxSUV) in recurrence prediction in patients with surgically resected NSCLC. Materials & methods: NSCLC patients (n=42, F:M =14:28, age $62.3{\pm}12.3$ y) who underwent curative resection after FDG-PET were enrolled. Twenty-nine patients had pathologic stage 1, and 13 had pathologic stage II. Thirty-one patients were additionally treated with adjuvant oral chemotherapy. MaxSUVs of primary tumors were analyzed for correlation with tumor recurrence and compared with pathologic or clinical prognostic indicators. The median follow-up duration was 16 mo (range, 3-26 mo). Results: Ten (23.8%) of the 42 patients experienced recurrence during a median follow-up of 7.5 mo (range, 3-13 mo). Univariate analysis revealed that disease-free survival (DFS) was significantly correlated with maxSUV (<7 vs. $\geq7$, p=0.006), tumor size (<3 cm vs. $\geq3$ cm, p=0.024), and tumor tell differentiation (well/moderate vs. poor, p=0.044). However, multivariate Cox proportional analysis identified maxSUV as the single determinant for DFS (p=0.014). Patients with a maxSUV of $\geq7$(n=10) had a significantly lower 1-year DFS rate (50.0%) than those with a maxSUV of <7 (n=32, 87.5%). Conclusion: MaxSUV is a significant independent predictor for recurrence in surgically resected NSCLC. FDG uptake can be added to other well-known factors in prognosis prediction of NSCLC.

목적 : PET에서 측정되는 FDG 섭취가 비소세포폐암의 예후예측인자로 인정받고 있으나 최대 표준화섭취계수(maximum standardized uptake value, 이하 maxSUV)의 예후예측 성능에 대해서는 충분한 연구가 이루어지지 않았다. 저자들은 수술로 제거된 비소세포폐암 환자에서 maxSUV의 재발예측 성능을 알아 보았다. 대상 및 방법 : FDG-PET을 실시한 후 4주 이내에 근치적인 수술을 시행받은 42명의 환자(여:남=14:28, 평균나이 $62.3{\pm}12.3$세)를 대상으로 하였으며 수술 후 병리학적인 stage는 29명은 stage I, 13명은 stage II이었다. 21명의 환자들은 수술 후 경구용 항암제 치료를 받았다. 추적관찰 기간(중앙값 16개월, 범위 3-26개월) 동안 재발여부와 maxSUV와의 연관성을 분석하였다. 결과 10명(23.8%, 10/42)의 환자에서 재발이 확인되었다(추적관찰 기간: 중앙값 7.5개월, 범위 3-13개월). 단변량분석에서 maxSUV (<7 vs. $\geq7$, p=0.006), 종양의 크기(<3 cm vs. $\geq3$ cm, p=0.024), 그리고 종양의 분화도(well/moderate vs. poor, p=0.044)가 비재발-생존기간과 유의한 상관이 있었다. Cox 위험도 모델을 이용한 다변량분석에서는 maxSUV만이 유일한 재발 예측인자이었다. (p=0.014) MaxSUV가 7이상인 환자들(n=10)은 1년 비재발 생존률이 50.0%인 반면에 maxSUV가 7미만인 환자들(n=32)은 1년 비재발 생존률이 87.5%이었다. 결론: MaxSUV는 수술로 제거된 비소세포폐암의 재발을 예측하는 독립적인 인자이었다. FDG 섭취 정도는 기존에 알려져 있는 인자들과 함께 비소세포폐암의 예후에 대한 유용한 정보를 제공할 것으로 기대된다.

Keywords

References

  1. AJCC Cancer Staging Manual. 6th ed. NY: Sringer; 2002. p. 167-177
  2. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. F-18 FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45
  3. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-9 https://doi.org/10.1016/j.jtcvs.2004.11.007
  4. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996;61: 1470-6 https://doi.org/10.1016/0003-4975(96)00104-X
  5. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with F-18 fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44
  6. Shankar LK, Sullivan DC. Functional imaging in lung cancer. J Clin Oncol 2005;23:3203-11 https://doi.org/10.1200/JCO.2005.08.854
  7. Duhaylongsod FG, Lowe VJ, Patz EF, Jr., Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by F-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-52 https://doi.org/10.1016/0003-4975(95)00754-9
  8. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on F-18 fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6 https://doi.org/10.1200/JCO.1999.17.10.3201
  9. Jeong HJ, Min JJ, Park JM, Chung JK, Kim BT, Jeong JM, et al. Determination of the prognostic value of F-18 fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23:865-70 https://doi.org/10.1097/00006231-200209000-00010
  10. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-60 https://doi.org/10.1200/JCO.2004.11.109
  11. www.intmed.mcw.edu/clincalc/body.html
  12. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Is standardised F-18 FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 2006;33:263-9 https://doi.org/10.1007/s00259-005-1953-2
  13. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. F-18 fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136-43 https://doi.org/10.1200/JCO.2005.06.129
  14. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of F-18 fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11-7 https://doi.org/10.1097/00006231-200401000-00003
  15. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 2000;27:1778-85 https://doi.org/10.1007/s002590000367
  16. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999;59:4709-14
  17. Caraco C, Aloj L, Chen LY, Chou JY, Eckelman WC. Cellular release of F-18 2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 2000;275:1 8489-94
  18. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. F-18 FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369-79 https://doi.org/10.1593/neo.04577
  19. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 2002;26:185-90 https://doi.org/10.1097/00004728-200203000-00004
  20. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993;34:414-9